Ysios Capital’s portfolio company Adcendo appoints Michael Pehl as Chief Executive Officer
07/07/2021 Nota de prensa YSIOS CAPITAL´S PORTFOLIO COMPANY ADCENDO APPOINTS MICHAEL PEHL AS CHIEF EXECUTIVE OFFICER. Adcendo, a biotech company developing innovative antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces today the appointment of Michael Pehl as Chief Executive Officer (CEO). Henrik Stage, co-founder of Adcendo, will move to the role of Chief…